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ABSTRACT
Introduction Neither the pathophysiology nor an effective 
treatment for heart failure with preserved ejection fraction 
(HFpEF) has been elucidated to date. The purpose of this 
ongoing study is to elucidate the pathophysiology and 
prognostic factors for patients with HFpEF admitted to 
participating institutes. We also aim to obtain insights into 
the development of new diagnostic and treatment methods 
by analysing patient background factors, clinical data and 
follow- up information.
Methods and analysis This study is a prospective, 
multicentre, observational study of patients aged ≥20 
years admitted due to acute decompensated heart failure 
with preserved left ventricular ejection fraction (≥50%) 
and elevated N- terminal- pro brain natriuretic peptide 
(NT- proBNP) (≥400 pg/mL). The study began in June 2016, 
with the participation of Osaka University Hospital and 
31 affiliated facilities. We will collect data on history in 
detail, accompanying diseases, quality of life, frailty score, 
medication history, and laboratory and echocardiographic 
data. We will follow- up each patient for 5 years, and 
collect outcome data on mortality, cause of death, and the 
number and cause of hospitalisation. The target number of 
registered cases is 1500 cases in 5 years.
Ethics and dissemination The protocol was approved 
by the Institutional Review Board (IRB) of Osaka University 
Hospital on 24 February 2016 (ID: 15471), and by the 
IRBs of the all participating facilities. The findings will be 
disseminated through peer- reviewed publications and 
conference presentations.
INTRODUCTION
The number of heart failure cases in devel-
oped countries is rapidly increasing due to 
the increasing number of elderly people.1 
In particular, a dramatic increase in cases 
of heart failure with preserved ejection frac-
tion (HFpEF), a disease that accounts for 
about half of patients with congestive heart 
failure, is a substantial public health problem 
in aged societies. However, despite the many 
previous studies, an effective treatment for 
HFpEF patients backed by valid evidence 
has yet to emerge. β-blockers, ACE inhibi-
tors, mineralocorticoid receptor antagonists 
and angiotensin receptor- neprilysin inhib-
itors improve the prognosis of patients with 
heart failure with reduced ejection fraction 
(HFrEF), but do not show efficacy in patients 
with HFpEF.2–5 The lack of an effective treat-
ment may be largely because researchers have 
been unable to categorise the phenotypes of 
HFpEF patients due to the heterogeneity and 
complexity of the pathogenesis of HFpEF 
Strengths and limitations of this study
 ► The Prospective, Multicenter, Observational Study 
on the Prognosis of Heart Failure with Preserved 
Ejection Fraction study has very detailed clinical, 
echocardiographic and laboratory data at multiple 
time points.
 ► A wide- range of heart failure with preserved ejection 
fraction patients will be enrolled and classified using 
detailed data.
 ► Long- term outcome data for 5 years, and data on 
exercise capacity, sympathetic imaging, quality of 
life (QOL) score, sleeping status and mental condi-
tion will be collected.
 ► Outcome data will be collected through the National 
Vital Statistics to ensure a high follow- up rate.
 ► All of the participating hospitals are located in a sin-
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itself, which includes not only myocardial diastolic 
dysfunction but also valvular dysfunction, vascular stiff-
ening, renal dysfunction and other comorbidities.6 To 
classify the heterogeneous phenotypes of HFpEF patients, 
detailed and comprehensive data from a large number of 
HFpEF patients is needed.
Several cohort studies of HFpEF patients have been 
reported in recent years.7–11 However, these studies have 
not been able to sufficiently clarify the pathogenesis of 
HFpEF. In addition, recent reports indicate that Japanese 
HFpEF patients are much older and less obese, and show 
a higher frequency of complication by atrial fibrillation 
than patients in western countries,10 11 suggesting the 
need for a specific database of Japanese HFpEF patients.
To overcome these issues, we designed a Prospective, 
Multicenter, Observational Study on the Prognosis of 
HFpEF (PURSUIT- HFpEF study). The PURSUIT- HFpEF 
study will collect detailed data from more than 1500 
hospitalised HFpEF patients with 5- year prognosis data. 
The study will enrol a wide range of HFpEF patients with 
few exclusion criteria, and collect detailed data on admis-
sion, at discharge and at 1 year after discharge to enable 
precise understanding of ‘real world’ HFpEF patients. 
Our strategy is to enrol heterogeneous and wide range of 
HFpEF patients with broad inclusion criteria and classify 
them using detailed clinical data. We also aim to collect 
mortality and cause of death data that is as complete as 
possible using the National Vital Statistics, which includes 
reports of death among all Japanese people. This study 
will add important data to aid in the pathophysiological 
classification of HFpEF, the establishment of prognostic 
factors and consequences of current treatments, and lead 
to the development of effective treatments specific for 
HFpEF patients. This paper describes details of the ratio-
nale and design of the PURSUIT- HFpEF study.
METHODS AND ANALYSIS
Design of PURSUIT-HFpEF study
The PURSUIT- HFpEF study is being conducted under a 
prospective, multicentre, observational design in which 
31 collaborating hospitals (1 university hospital, 30 
regional core centres) in the Osaka region of Japan will 
collect demographic, clinical and outcome data from 
patients hospitalised due to congestive HFpEF (UMIN 
ID: UMIN000021831). The study began in June 2016. 
This study complies with the Declaration of Helsinki, and 
the study protocol was approved by the ethics committee 
of each participating hospital. Briefly, patients hospital-
ised due to the diagnosis of decompensated congestive 
heart failure who meet the inclusion criteria but not the 
exclusion criteria (box 1) will be prospectively registered 
and followed for 5 years (figure 1). Patients who agree to 
receive follow- up will provide written informed consent.
Eligibility criteria
We will enrol patients hospitalised with the diagnosis of 
decompensated heart failure based on the Framingham 
criteria and who meet the criteria of left ventricular ejec-
tion fraction (LVEF) ≥50% in transthoracic echocardiog-
raphy (TTE) and brain natriuretic peptide (BNP) ≥100 pg/
mL or N terminal- proBNP (NT- proBNP) ≥400 pg/mL on 
admission. Heart failure is defined as a clinical syndrome 
that results from structural or functional impairment 
of ventricular filling or ejection of blood.12 The Fram-
ingham criteria are widely used diagnostic criteria for 
congestive heart failure proposed by McKee et al.13 Major 
criteria include physician- assessment of neck- vein disten-
sion, rales, S3 gallop, venous pressure >16 cm of water, 
hepatojugular reflux and weight loss of 4.5 kg in 5 days 
due to diuretic therapy. Minor criteria are ankle oedema, 
night cough, dyspnoea on exertion, hepatomegaly, tachy-
cardia and weight loss. ‘Definite congestive heart failure’ 
is defined as having at least two major criteria, or one 
major criteria and two minor criteria. We defined the cut- 
off value of LVEF for HFpEF as ≥50% according to the 
corresponding guideline.12 On admission, while either 
BNP or NT- proBNP is acceptable as an inclusion crite-
rion, confirmation of NT- proBNP level will be mandatory 
in this study. Electrochemiluminescence immunoassay 
developed by Roche Diagnostics will be recommended 
for the measurement of NT- proBNP.
We will exclude patients with severe aortic stenosis, 
aortic regurgitation, mitral stenosis or mitral regurgi-
tation due to structural changes in valves detected by 
TTE on admission. We will also exclude patients aged 
under 20 years, those with acute coronary syndrome on 
admission, life expectancy of less than 6 months due to 
prognosis for non- cardiac diseases, previous heart trans-
plantation, and those judged ineligible for the study by 
the attending physician (box 1). We will not exclude 
patients with haemodialysis or bradycardia, consistent 
with our focus on studying real- world HFpEF patients. 
Regarding patients on haemodialysis, we consider that 
Box 1 Inclusion and exclusion criteria
Inclusion criteria
Patients admitted due to decompensated heart failure (based on the 
Framingham heart failure criteria) who meet the criteria below.
 ► Left ventricular ejection fraction ≥50% as measured using the mod-
ified Simpson method or Teichholz method in transthoracic echocar-
diography (TTE) on admission.
 ► Brain natriuretic peptide (BNP) ≥100 pg/mL or N- terminal- pro BNP 
≥400 pg/mL by laboratory test on admission.
Exclusion criteria
 ► Patients with severe aortic stenosis, aortic regurgitation, mitral ste-
nosis or mitral regurgitation due to structural changes in valves de-
tected using TTE on admission.
 ► Patients aged under 20 years old.
 ► Patients with acute coronary syndrome on admission.
 ► Patients with poor life expectancy within 6 months due to non- 
cardiac diseases.
 ► Patients who had previously undergone heart transplantation.
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we can ensure the accuracy of HFpEF diagnosis in these 
patients owing to our requirement for not only BNP level 
but also a diagnosis of heart failure by a cardiologist. 
Patients with secondary cardiomyopathies such as amyloi-
dosis or Fabry disease may also be enrolled; however, 
we will collect the final diagnosis of underlying cardiac 
disease which caused HFpEF, and this will enable the 
exclusion of specific cardiac conditions from the analysis 
if necessary.
Data collection
Research cardiologists and specialised research nurses 
will record patient data during hospital stays and desig-
nated visits after discharge. Data collection will be 
performed using an electronic data capture system inte-
grated into the electronic medical records developed at 
Osaka University.14 In- hospital data will be entered into 
the system and transferred to the data collection centre 
via a secure internet connection for processing and anal-
ysis. Collaborating hospitals will be encouraged to enrol 
consecutive patients with heart failure with preserved 
ejection fraction irrespective of treatment.
Blood samples will be obtained at admission, before 
discharge and 1 year after discharge. Oral medications will 
be evaluated at admission and before discharge. The Six- 
Minute Walk Test will be administered before discharge.
In- hospital data will be collected on admission and 
at discharge. ‘On admission’ is defined as the period 
between admission and approximately 48 hours after 
admission, and ‘at discharge’ as the period between 
approximately 48 hours after admission and 30 days 
after discharge. In this study, we consider ‘at discharge’ 
to be a stable phase. Contrary to the timing of admis-
sion, the timing of recovery from the acute decompen-
sated phase to the stable phase and discharge varies 
markedly, depending on the severity of the worsening of 
heart failure on admission. Some patients may recover 
to the stable phase very early after admission, and leave 
the hospital within 3 or 4 days after admission and then 
be followed at outpatient clinics. We will collect data ‘at 
discharge’ for these patients either during hospitalisation 
or at outpatient clinics. Accordingly, we define a broad 
range of times as ‘at discharge’. Investigators are required 
to collect as much data as possible at discharge when 
patients are stable.
Patient demographics
We will collect data on age, sex, height, weight, body mass 
index, blood pressure (systolic, diastolic), heart rate, 
peripheral capillary oxygen saturation (SpO2; room air), 
activities of daily living using the Clinical Frailty Scale,15 
history of hospitalisation for heart failure, New York 
Heart Association class, Nohria- Stevenson class,16 clin-
ical scenario class17 and matched Framingham criteria.13 
SpO2 in room air will be measured only when patients 
can tolerate room air.
Data on comorbidities including atrial fibrillation, 
hypertension, diabetes mellitus, dyslipidaemia, smoking, 
alcohol consumption, hyperuricaemia, chronic obstruc-
tive pulmonary disease and chronic kidney disease, 
history of hospitalisation for heart failure, prior myocar-
dial infarction, prior stroke and malignant diseases will 
also be collected. We will assess quality of life using 
the 5- Level EuroQol 5 Dimension (EQ- 5D- 5L),18 19 
sleep quality using the Pittsburgh Sleep Quality Index 
(PSQI)20 21 and depression using the Self- rating Depres-
sion Scale (SDS)22 before and 1 year after discharge. 
EQ- 5D- 5L, PSQI and SDS will be performed in a self- 
reported manner.
Medication and therapeutics
We will collect data on the use of catecholamines, carper-
itides, vasodilators, antiplatelets, angiotensin- converting 
enzyme inhibitors, angiotensin receptor blockers, calcium 
channel blockers, β-blockers, α-blockers, diuretics, miner-
alocorticoid receptor antagonists, anticoagulants, antiar-
rhythmic drugs, statins, glucose- lowering drugs and uric 
acid- lowering drugs on admission, at discharge and 1 year 
after discharge. In addition, implementation of oxygen 
inhalation, respirator use and intubation during hospital-
isation will be reported.
Figure 1 Overview of the Prospective, Multicenter, Observational Study on the Prognosis of Heart Failure with Preserved 
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Laboratory data, echocardiography examination and other 
tests
Laboratory data will be obtained on admission, before 
discharge, and 1 year after discharge. Laboratory data 
include complete blood count and serum chemistry. 
Serum chemistry includes renal and liver tests, and 
tests for electrolytes. Transthoracic echocardiographic 
parameters will be obtained immediately after admis-
sion, before discharge, and 1 year after discharge. We 
will measure LVEF by either the Teichholz or modified 
Simpson method on admission, and by both at discharge 
and 1 year after discharge. Measuring LVEF only by Teich-
holz method will be allowed because of the difficulty 
of performing the modified Simpson method in acute 
settings. We will obtain data on cardiac chamber size and 
function, Doppler measurements and tissue Doppler 
measurements.
We will also collect data on standard 12- lead ECG and 
chest X- ray on admission, before discharge and at desig-
nated annual visits after discharge.
123I MIBG cardiac scintigraphy
Although it is well known that sympathetic nerve activity 
plays an important role in the pathogenesis of HFrEF, its 
role in HFpEF remains to be elucidated. 123I MIBG cardiac 
scintigraphy will be performed at discharge or soon after 
discharge at designated facilities. All patients will receive 
111 MBq (3 mCi) of iodine-123- MIBG (Fuji Film Toyama 
Chemical, Tokyo, Japan) after an overnight fast and subse-
quently undergo planar imaging of the anterior thorax 
using a nuclear camera equipped with low- energy, general- 
purpose collimators. The scan at the early phase will be 
obtained at 15–20 min after injection, and that at the late 
phase at 3 hours after the early phase. Image processing 
will be performed locally at each institution. The heart- to- 
mediastinum ratio (HMR) on early and late images and the 
washout rate will be assessed using a standardised method 
for automatic setting of the region of interest (ROI).23 24 
The software used to set the automatic ROI includes cross- 
calibration of HMR among hospitals to normalise differ-
ences due to variations in the types of collimator used. The 
algorithm is based on phantom studies conducted in all 
participating hospitals, and converts the HMR obtained 
from a low- energy type collimator to a value comparable 
to that obtained using a medium- energy type collimator. 
The washout rate will be calculated based on background 
correction and decay correction.
Cardiac catheterisation test
Right- sided and left- sided heart catheterisation tests will 
be performed at the discretion of the attending physi-
cian. Haemodynamic data on right atrial pressure, right 
ventricular end- diastolic pressure, main pulmonary 
artery pressure and coronary angiographic data will be 
recorded.
Follow-up schedule
Enrolled patients will be followed up at out- patient clinics 
at least once a year, and outcome data during the period 
from the previous visit will be collected. Outcome events 
include cardiogenic death, non- cardiogenic death and 
readmission due to cardiogenic or non- cardiogenic 
causes. The primary outcome of this study is all- cause 
mortality. However, since this study is explorative and 
observational, we will also set a primary endpoint in each 
analysis according to the aim of the analysis. Follow- up 
will be performed either by direct contact or telephone 
interview with patients. For patients whose survival infor-
mation cannot be determined by these means, the data 
of National Vital Statistics of Japan will be used under 
the permission of the Ministry of Health, Labour and 
Welfare in accordance with the Statistics Act in Japan. 
The National Vital Statistics includes all death records in 
Japan reported by prefectural public health centres.
Study organisation
Osaka Cardiovascular Conference
The Osaka Cardiovascular Conference (OCVC) consists 
of cardiologists belonging to the Osaka University Grad-
uate School of Medicine or one of 30 affiliated hospitals 
in Osaka, Japan. The OCVC was launched in 2014 to 
investigate clinical questions in the cardiovascular field.
The PURSUIT- HFpEF study is being conducted by the 
OCVC and its collaborators, which form the OCVC- Heart 
Failure Investigators. A total of 1500 study cases are expected 
to be registered in 5 years, with 300 cases registered per year. 
This study started enrolment in April 2016, will stop enrol-
ment in March 2021 and will continue until March 2026 to 
allow the completion of follow- up for all patients.
Statistical considerations
Considering the explorative and observational nature 
of the current study, no formal sample size will be calcu-
lated. We will enrol all consecutive patients who fulfil 
the criteria among those admitted to participating facil-
ities. We roughly surveyed the number of past patients 
who would have fulfilled criteria in each participating 
facility, and derived a number of about 300 patients per 
1 year. Continuous data will be expressed as mean±SD 
or median with IQR for all variables collected from the 
entire population or specific subgroups. Categorical vari-
ables will be reported as percentages. Specific analyses 
including multivariable regression models will be used to 
explore the relationships between baseline covariates and 
predefined post- baseline endpoints, as appropriate. We 
will perform Kaplan- Meier analysis for survival analysis, 
and univariate and multivariate Cox regression analyses 
for calculation of unadjusted and adjusted HRs. In addi-
tion, details of method of analysis will be provided for 
each analysis. Handling of missing values will be decided 
based on the type and frequency of missing values. A p 
value <0.05 will be considered statistically significant.
Patient and public involvement
We will not involve patients or the public in the devel-
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research results will be disseminated through publications 
or social media.
Ethics and dissemination
The study protocol has been approved by the Institutional 
Review Board of all participating facilities. namely Kansai 
Rosai Hospital Institutional Review Board, Kawachi 
General Hospital Ethics Committee, Osaka Rosai Hospital 
Ethics Committee, Higashiosaka City Medical Center 
Institutional Review Board, Osaka Prefectural Hospital 
Organization Osaka General Medical Center Institutional 
Review Board, Hyogo Prefectural Nishinomiya Hospital 
Ethics Committee, Ikeda Municipal Hospital Ethics 
Committee, Kawanishi City Hospital Institutional Review 
Board, Rinku General Medical Center Ethics Committee, 
Saiseikai Senri Hospital Ethics Committee, Yao Municipal 
Hospital Institutional Review Board, Kawasaki Hospital 
Ethics Committee, Minoh City Hospital Ethics Committee, 
National Hospital Organization Osaka National Hospital 
Second Institutional Review Board, Kano General 
Hospital Ethics Committee, Osaka International Cancer 
Institute Institutional Review Board, Toyonaka Munic-
ipal Hospital Ethics Committee, Kinan Hospital Ethics 
Committee, Japan Community Health Care Organi-
zation Osaka Hospital Ethics Committee, Kobe Ekisa-
ikai Hospital Ethics Committee, Sakurabashi Watanabe 
Hospital Ethics Committee, Sumitomo Hospital Research 
Ethics Committee, Suita Municipal Hospital Institutional 
Review Board, Kinki Central Hospital Ethics Committee, 
Osaka Police Hospital Institutional Review Board, Japan 
Community Health Care Organization Hoshigaoka 
Medical Center Institutional Review Board, National 
Hospital Organization Osaka Minami Medical Center 
Institutional Review Board, Japan Community Health 
Care Organization Osaka Minato Central Hospital Ethics 
Committee, Amagasaki Chuo Hospital Ethics Committee, 
Otemae Hospital Institutional Review Board and Osaka 
University Hospital Clinical Research Review Committee.
We will present analysed data at domestic and inter-
national medical conferences, and will publish them as 
scientific papers in peer- reviewed journals.
DISCUSSION
In this study, we will enrol a wide range of HFpEF patients 
diagnosed with definite heart failure using the Fram-
ingham criteria, and collect their detailed clinical data 
and long- term prognosis data. Our study will have distinct 
features compared with previous studies that will enable 
the conduct of in- depth analysis and elucidation of the 
characteristics and pathophysiology of HFpEF.
A number of previous studies have attempted to eluci-
date the pathophysiology of HFpEF, which is known to 
be very complex and heterogeneous.6 The Organized 
Program to Initiate Lifesaving Treatment in Hospitalized 
Patients with Heart Failure (OPTIMIZE- HF) registry is a 
large scale registry of 48 612 patients hospitalised for HF, 
including 10 072 patients with LVEF >50%, and contains 
comprehensive data from both admission and discharge, 
and outcome data at 60 and 90 days after enrolment.7 The 
Acute Decompensated Heart Failure National Registry 
(ADHERE) is the largest database, containing more 
than 100 000 patients with heart failure, including 26 322 
patients with LVEF ≥50%. This database examines almost 
80 variables and in- hospital outcomes, and therefore 
seems relatively less comprehensive than the former two 
studies.8 While OPTIMIZE- HF7 and ADHERE8 examined 
very large sample sizes of >10 000 patients and obtained 
prognosis data, data items related to clinical tests were 
limited, and prognosis data were limited to short- term 
outcomes (in- hospital or 60–90 days after discharge). 
Further, ADHERE had a retrospective study design. 
The Enhanced Feedback for Effective Cardiac Treat-
ment study is another cohort study that enrolled HFpEF 
patients with LVEF ≥50% and obtained 1- year prognosis 
data.9 However, sample size was relatively limited (880 
patients) and the study design was retrospective, as in the 
case with ADHERE. The Japanese CArdiac REgistry in 
CHF- CARDiology (JCARE- CARD) is a prospective obser-
vational study which enrolled 2675 patients hospitalised 
with heart failure, including 429 patients with LVEF ≥50%, 
and contains data from both admission and discharge, 
as well as outcome data at 1 year after admission.10 
Recently, the Japanese Heart Failure Syndrome with 
Preserved Ejection Fraction (JASPER) registry reported 
the characteristics and 2- year prognosis of 535 patients 
with HFpEF, with detailed echocardiographic and labo-
ratory data.11 JCARE- CARD and JASPER are prospective 
studies conducted in Japan, which have obtained long- 
term follow- up data. JCARE- CARD included not only 
HFpEF patients but also HFrEF patients, which enabled 
comparisons between these patients. JASPER obtained 
detailed clinical, echocardiographic and laboratory data, 
which enabled in- depth analysis of patient characteris-
tics and pathophysiology. A possible limitation of these 
two studies is the sample size (JCARE- CARD: 401 cases, 
JASPER: 535 cases). Most recently, the ASIAN- HF group 
reported detailed characteristics, echocardiographic 
data and outcomes of an international registry of 1204 
HFpEF patients from 11 Asian regions.25 The VIP- HF 
study is an ongoing prospective registry of 250 HFpEF 
patients designed to evaluate the incidence of ventric-
ular arrhythmias in HFpEF using an implantable loop 
recorder (NCT01989299). This study also aims pheno-
typing of this disease, using comprehensive laboratory 
testing, echocardiography, cardiac MRI, bone scintig-
raphy for cardiac amyloidosis, and the Six- Minute Walk 
Test, and may produce very important findings, partic-
ularly regarding cardiac pathophysiologies in HFpEF. 
Our present PURSUIT- HFpEF study will have a relatively 
large sample size (target patient number >1500), and very 
detailed clinical, echocardiographic and laboratory data 
on admission, at discharge and 1 year after discharge. In 
addition, our study will collect long- term outcome data for 
5 years, and data on exercise capacity (Six- Minute Walk 
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QOL score (EQ- 5D- 5L), frailty (the Clinical Frailty Scale 
(CFS)), sleeping status (PSQI) and mental condition 
(SDS test). Data regarding not only cardiac conditions 
but also extracardiac conditions will be obtained in this 
study. Therefore, our study will comprise a more compre-
hensive database of HFpEF patients than previous studies. 
The broad inclusion criteria and few exclusion criteria 
will enable the inclusion of ‘real- world’ HFpEF patients. 
Detailed data items regarding both cardiac and extracar-
diac abnormalities will be useful to classify real- world, 
heterogeneous HFpEF patients. These characteristics of 
our study are expected to allow for a more detailed char-
acterisation and elucidation of HFpEF.
In this study, we will sequentially collect echocardio-
graphic and laboratory data at admission, discharge and 
follow- up, which may be another distinctive feature of 
this study. OPTIMIZE- HF obtained data both at admis-
sion and discharge, but not at follow- up, and data items 
on echocardiography are very limited.26 JCARE- CARD 
collected echocardiographic data and laboratory data 
only on admission.27 In JASPER, laboratory test data were 
obtained both at admission and discharge, but echocar-
diography data was obtained only once.11 Therefore, 
the sequential collection of both echocardiography and 
laboratory data in our study is unique, and will be useful 
for clarifying details of the time course of changes in 
HFpEF patients and the effects of changes in extracar-
diac and cardiac conditions during hospitalisation or 
after discharge on prognosis, which are not well known.
We will collect the outcome data through direct contact 
or telephone interview with patients or their family 
members, and also through the National Vital Statistics. 
Potential limitations of prospective observational studies 
in clinical settings are missing outcome data due to loss to 
follow- up, and the lack of determination of cause of death 
in patients who died out of hospital. Because HFpEF 
patients are generally elderly, loss to follow- up due to 
discontinuation of clinic visits is a frequent concern. 
The National Vital Statistics in Japan collects the data 
on all death records that occur in Japan. This includes 
the date and cause of death as diagnosed by physicians, 
and has been used in community- based epidemiological 
research.28 29 This database would clarify the survival and 
cause of death of patients who cannot be followed up in 
the past clinical studies.
There are several limitations to the design of the 
PURSUIT- HFpEF study. First, all of the participating hospi-
tals are located in a single region of Japan, which may cause 
some bias in patient background. Second, the sample size 
is limited compared with previous large scale studies.8 26 
Therefore, detailed classification of HFpEF patients may be 
limited. Third, because the treatment and care of patients 
will be performed at the discretion of the attending physi-
cians, caution is needed when interpreting the analysed 
data. Fourth, because evaluation of imaging data (eg, echo-
cardiography, electrocardiography, MIBG scintigraphy) and 
blood samples will be performed locally without validation of 
inter- institutional variation, we cannot exclude the potential 
for measurement bias among facilities or investigators. Fifth, 
since no structural or functional alterations on echocardiog-
raphy are needed for enrolment, this may result in inclusion 
of patients who do not qualify or are generally not accepted 
as having HFpEF. In addition, patients with recovered LVEF 
who previously had reduced LVEF will not be excluded due 
to technical difficulties in this study, despite the fact that 
these patients have a distinct prognosis to those with HFpEF. 
Finally, this study will include only patients admitted due to 
decompensated heart failure, and not patients who have not 
been admitted. Therefore, it is possible that our study popu-
lation is a relatively sick cohort.
In conclusion, we have begun a PURSUIT- HFpEF. 
This study will enrol a wide range of patients diagnosed 
with HFpEF and collect detailed information at multiple 
time points after enrolment. It is therefore expected to 
produce a detailed sequential database of HFpEF patients 
to date. Statistical analysis of the obtained data is expected 
to lead to elucidation of the pathophysiology of HFpEF 
in the ‘real world’ and the development of evidence for 
appropriate interventions for patients with HFpEF.
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